Zobrazeno 1 - 2
of 2
pro vyhledávání: '"LK Jennifer"'
Autor:
HR Kenneth, BH Carlos, T Alastair, HZ Amy, RS Akshara, MK Rashmi, T Debu, L Bora, GH Sharon, UT Naoto, V Vicente, C-M Mariana, MA Elizabeth, LK Jennifer
Publikováno v:
Cancer Research. 78:P5-20
Background: Pertuzumab (P) in combination with trastuzumab (H) based chemotherapy is currently FDA- approved as a standard neoadjuvant treatment for patients with clinical stage II-III HER2-positive (HER2+) breast cancer (BC). The chemotherapy backbo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7d8855d7cebd044eea46fbc376dac92f
https://doi.org/10.1158/1538-7445.sabcs17-p5-20-10
https://doi.org/10.1158/1538-7445.sabcs17-p5-20-10
Autor:
KW Evans, Emily Tarco, Agda Karina Eterovic, Xiaofeng Zheng, Ken Chen, LK Jennifer, Debu Tripathy, Argun Akcakanat, Stephen Scott, GB Mills, Dalliah M. Black, Coya Tapia, Erkan Yuca, Funda Meric-Bernstam, N Paez Arango
Publikováno v:
Cancer Research. 77:P4-06
Background: Patients with triple negative breast cancer (TNBC) that have significant residual disease following neoadjuvant therapy have a poorer prognosis. The difficulty in developing improved treatment strategies for these patients is compounded b
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::241226544c19a7c70f228af274723530
https://doi.org/10.1158/1538-7445.sabcs16-p4-06-04
https://doi.org/10.1158/1538-7445.sabcs16-p4-06-04